Adherence to Anti-VEGF Treatment in Patients with Neovascular Age-Related Macular Degeneration: A Real-World Study

Macular Diseases

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Int J Retina Vitreous

Grimaldi G, Cancian G, Paris A, Clerici M, Volpe G, Menghini M

doi: 10.1186/s40942-024-00586-w

Macular Diseases

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Clin Exp Ophthalmol

Spooner K, Broadhead G, Fraser-Bell S, Hong T, Wong JG, Chang AA

doi: 10.1111/ceo.14559

Macular Diseases

Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration

Br J Ophthalmol

Borrelli E, Foti C, Ulla L, Porreca A, Introini U, Grassi MO, Viggiano P, Peronetti M, Toscani R, Boscia G, Termite AC, Gennaro C, Marolo P, Boscia F, Bandello F, Reibaldi M

doi: 10.1136/bjo-2024-326152

Macular Diseases

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Ophthalmol Ther

Mhmud H, Vermeulen JP, Tigchelaar-Besling OAM, Verbraak FD, Barthelmes D, Gillies M, Ponsioen TL, Klaver CCW

doi: 10.1007/s40123-025-01178-z

Macular Diseases

Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study

Acta Ophthalmol

Falemban AH, Söderberg-Löfdal K, Jonsson F, Almlöf-Sarman S, von Euler M, Westborg I

doi: 10.1111/aos.17534

Macular DiseasesRetinal Diseases

Persistence of Retinal Fluid after Anti-VEGF treatment for neovascular age-related macular degeneration: A Systematic Review and Meta-Analysis

Ophthalmol Retina

Ting Yap DW, Jyn Tan BK, Yi Chong KT, Wong TY, Gemmy Cheung CM

doi: 10.1016/j.oret.2025.01.010

Macular Diseases

Choroidal thickness after anti-VEGF in typical neovascular age-related macular degeneration - A systematic review and meta-analysis

Surv Ophthalmol

Hoven E, Michelet JT, Vettore MV, Lagali N

doi: 10.1016/j.survophthal.2024.09.011

Macular Diseases

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Ophthalmol Ther

Cancian G, Paris A, Agliati L, Rizzato A, Clerici M, Volpe G, Menghini M, Grimaldi G

doi: 10.1007/s40123-024-01036-4

Macular Diseases

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series

BMC Ophthalmol

Bantounou MA, Elsheikh M, Ijasan A, Santiago C

doi: 10.1186/s12886-025-03953-9

Related content

Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Incidence and reasons for discontinuation of anti-VEGF treatment in neovascular age-related macular degeneration

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study

Persistence of Retinal Fluid after Anti-VEGF treatment for neovascular age-related macular degeneration: A Systematic Review and Meta-Analysis

Choroidal thickness after anti-VEGF in typical neovascular age-related macular degeneration - A systematic review and meta-analysis

One-Year Real-World Outcomes of Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration

Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series